Laura Korin, Doctor of the Haematology Service and Unit Of Haematopoietic Transplantation (UTH) of the Alexander Fleming Institute, shared a post on X:
“Do we envision the future of first-line treatment for diffuse large B-cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) plus targeted agents (X) according to genetic subtype classification or will be move towards a genetic agnostic strategy such as R-CHOP plus bispecific antibodies (BsAb)?”
More updates from ASH25 on OncoDaily.